NUVA (NuVasive, Inc.) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.

NUVA does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for NUVA and 80,000+ other tickers.
See exactly how NUVA's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for NUVA and 80,000+ other tickers.
NuVasive, Inc. is a medical technology firm focused on creating, producing, and distributing comprehensive procedural solutions for spinal operations. The company offers a range of surgical access instruments, such as the Maxcess integrated split-blade retractor system, which facilitates less-invasive surgical approaches by significantly reducing soft tissue disruption during spinal procedures. Additionally, NuVasive manufactures specialized spinal implants designed to improve spinal fusion by optimizing the osseointegration and biomechanical characteristics of materials like porous titanium…

Globus Medical faced market backlash post-merger with NuVasive, but Q1 FY 2024 showed strong growth and integration efforts. Management revised net sales guidance for FY 2024, aiming for high growth and increased profits with lower operating costs. Valuation scenarios suggest potential for risk capital unlock, and a buy rating is supported on fundamentals and cash flow estimates.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

SAN DIEGO , Aug. 30, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced it will continue its partnership with the Scoliosis Research Society (SRS) as a double diamond sponsor and will attend the 58th Annual Meeting held September 6-9, 2023, in Seattle. "We partner with esteemed societies like SRS because of our shared dedication to clinical research, education, and thought leadership around advancing patient care, especially in the challenging deformity segment," said Chris Barry, chief executive officer at NuVasive.

NEW YORK , Aug. 28, 2023 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600 effective prior to the opening of trading on Friday, September 1: Goosehead Insurance Inc. (NASD: GSHD) will replace NuVasive Inc. (NASD: NUVA) in the S&P SmallCap 600. S&P MidCap 400 constituent Globus Medical Inc. (NYSE: GMED) is acquiring NuVasive in a deal expected to close soon pending final conditions.

NuVasive's (NUVA) second-quarter 2023 results reflect the robust performance of the U.S. Cervical business.